Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Fortunato Morabito, Massimo Gentile, Paola Monti, Anna Grazia Recchia, Paola Menichini, Mamdouh Skafi, Moien Atrash, Giuseppa De Luca, Sabrina Bossio, Hamdi Al-Janazreh, Sara Galimberti, Zaidoun Salah, Lucio Morabito, Alham Mujahed, Musa Hindiyeh, Mariella Dono, Franco Fais, Giovanna Cutrona, Antonino Neri, Giovanni Tripepi, Gilberto Fronza & Manlio Ferrarini. (2020) TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. Expert Opinion on Investigational Drugs 29:8, pages 869-880.
Read now
Read now
Xin Huang, Si Chen, Qi Shen, Shaohua Chen, Lijian Yang, Piotr Grabarczyk, Grzegorz K Przybylski, Christian A Schmidt & Yangqiu Li. (2011) Down regulation of BCL11B expression inhibits proliferation and induces apoptosis in malignant T cells by BCL11B-935-siRNA. Hematology 16:4, pages 236-242.
Read now
Read now
Jun Ho Yi, Seok Jin Kim, Young Hyeh Ko & Won Seog Kim. (2011) Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. Leukemia & Lymphoma 52:2, pages 317-320.
Read now
Read now
Christiane Querfeld, Neha Mehta, Steven T. Rosen, Joan Guitart, Alfred Rademaker, Pedram Gerami & Timothy M. Kuzel. (2009) Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leukemia & Lymphoma 50:12, pages 1969-1976.
Read now
Read now
Joseph R. Berger, Sidney A. Houff & Eugene O. Major. (2009) Monoclonal antibodies and progressive multifocal leukoencephalopathy. mAbs 1:6, pages 583-589.
Read now
Read now
Michael Hudecek, Larry D Anderson Jr, Tetsuya Nishida & Stanley R Riddell. (2009) Adoptive T-cell therapy for B-cell malignancies. Expert Review of Hematology 2:5, pages 517-532.
Read now
Read now
John C. Morris, Thomas A. Waldmann & John E. Janik. (2008) Receptor-Directed Therapy of T-Cell Leukemias and Lymphomas. Journal of Immunotoxicology 5:2, pages 235-248.
Read now
Read now
Kerry Ann Sleigh, Mark E. F. Smith & Simon A. J. Rule. (2008) Cardiac involvement with mycosis fungoides: Could this explain alemtuzumab toxicity?. Leukemia & Lymphoma 49:10, pages 2022-2024.
Read now
Read now
Articles from other publishers (18)
Rahela Zaman, Rowshan Ara Islam & Ezharul Hoque Chowdhury. (2022) Evolving therapeutic proteins to precisely kill cancer cells. Journal of Controlled Release 351, pages 779-804.
Crossref
Crossref
Maciej Borówka, Stanisław Łącki-Zynzeling, Michał Nicze, Sylwia Kozak & Jerzy Chudek. (2022) Adverse Renal Effects of Anticancer Immunotherapy: A Review. Cancers 14:17, pages 4086.
Crossref
Crossref
Pedram Shafiei-Jahani, Doumet Georges Helou, Benjamin P. Hurrell, Lauriane Galle-Treger, Emily Howard, Christine Quach, Jacob D. Painter, Marshall Fung, Richard Lo, Hooman Allayee & Omid Akbari. (2021) CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation. Mucosal Immunology 14:4, pages 899-911.
Crossref
Crossref
Z Li, S Richards, H K Surks, A Jacobs & M A Panzara. (2018) Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clinical and Experimental Immunology 194:3, pages 295-314.
Crossref
Crossref
Kiat Ruxrungtham, Sunee Sirivichayakul, Supranee Buranapraditkun & Werner Krause. (2016) Alemtuzumab-induced elimination of HIV-1-infected immune cells. Journal of Virus Eradication 2:1, pages 12-18.
Crossref
Crossref
John Anthonypillai & Julian L. Ambrus. 2016. Systemic Vasculitides: Current Status and Perspectives. Systemic Vasculitides: Current Status and Perspectives
407
423
.
Yu ChenSichu LiuQi ShenXianfeng ZhaHaitao ZhengLijian YangShaohua ChenXiuli WuBo LiYangqiu Li. (2013)
Differential Gene Expression Profiles of
PPP2R5C
-siRNA-Treated Malignant T Cells
. DNA and Cell Biology 32:10, pages 573-581.
Crossref
Crossref
Rotem Kedar, Ofra Sabag, Michal Licthenstein & Haya Lorberboum‐Galski. (2012) Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment. Cancer 118:24, pages 6089-6104.
Crossref
Crossref
David Oscier, Claire Dearden, Efrem Eren, Christopher Fegan, George Follows, Peter Hillmen, Tim Illidge, Estella Matutes, Don W. Milligan, Andrew Pettitt, Anna Schuh & Jennifer Wimperis. (2012) Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. British Journal of Haematology 159:5, pages 541-564.
Crossref
Crossref
Steven P. TreonJacob D. SoumeraiZachary R. HunterChristopher J. PattersonLeukothea IoakimidisBrad Kahl & Michael Boxer. (2011) Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood 118:2, pages 276-281.
Crossref
Crossref
Edward Rosenow IIIAlbert Polito. 2010. Drug-induced and Iatrogenic Respiratory Disease. Drug-induced and Iatrogenic Respiratory Disease.
Gerhard Sissolak, June Juritz, Dagmar Sissolak, Lucille Wood & Peter Jacobs. (2010) Lymphoma – Emerging realities in sub-Saharan Africa. Transfusion and Apheresis Science 42:2, pages 141-150.
Crossref
Crossref
Gheath Alatrash, Maher Albitar, Susan OâBrien, Xuemei Wang, Taghi Manshouri, Stefan Faderl, Alessandra Ferrajoli, Jan Burger, Guillermo Garcia-Manero, Hagop M. Kantarjian, Susan Lerner, Michael J. Keating & William G. Wierda. (2010) Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). British Journal of Haematology 148:3, pages 386-393.
Crossref
Crossref
Lucille Wood, Jonathan Haveman, June Juritz, Herman Waldmann, Geoffrey Hale & Peter Jacobs. (2009) Immunohematopoietic stem cell transplantation in Cape Town. Hematology/Oncology and Stem Cell Therapy 2:2, pages 320-332.
Crossref
Crossref
Gabriele Multhoff & Sabrina T. Astner. 2009. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies
129
145
.
I. Aurer. (2007) E13 Non-Hodgkin lymphoma: how to proceed. Leukemia Research 31, pages S23-S25.
Crossref
Crossref
. (2007) Current Awareness in Hematological Oncology. Hematological Oncology 25:3, pages 148-155.
Crossref
Crossref
Kieron Dunleavy, Wyndham H Wilson & Elaine S Jaffe. (2007) Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Current Opinion in Hematology 14:4, pages 348-353.
Crossref
Crossref